PURPOSE: Oncolytic adenoviruses are promising tools for cancer therapy. Although several clinical reports have indicated both safety and promising antitumor capabilities for these viruses, there are only a few examples of complete tumor eradication. Thus, the antitumor efficacy of oncolytic adenoviruses needs to be improved. One potentially useful approach is combination with radiotherapy. EXPERIMENTAL DESIGN: To target systemically administered radioiodide to tumors, we created Ad5/3-Delta24-human sodium iodide symporter (hNIS), a Rb-p16 pathway selective infectivity enhanced oncolytic adenovirus encoding hNIS. RESULTS: Ad5/3-Delta24-hNIS replication effectively killed prostate cancer cells in vitro and in vivo. Also, the virus-mediated radioiodide uptake into prostate cancer cells in vitro and into tumors in vivo. Furthermore, Ad5/3-Delta24-hNIS with radioiodide was significantly more effective than virus alone in mice with prostate cancer xenografts. CONCLUSIONS: These results suggest that oncolytic adenovirus-mediated targeted radiotherapy might be a potentially useful option for enhancing the efficacy or adenoviral virotherapy.
PURPOSE: Oncolytic adenoviruses are promising tools for cancer therapy. Although several clinical reports have indicated both safety and promising antitumor capabilities for these viruses, there are only a few examples of complete tumor eradication. Thus, the antitumor efficacy of oncolytic adenoviruses needs to be improved. One potentially useful approach is combination with radiotherapy. EXPERIMENTAL DESIGN: To target systemically administered radioiodide to tumors, we created Ad5/3-Delta24-humansodium iodide symporter (hNIS), a Rb-p16 pathway selective infectivity enhanced oncolytic adenovirus encoding hNIS. RESULTS:Ad5/3-Delta24-hNIS replication effectively killed prostate cancer cells in vitro and in vivo. Also, the virus-mediated radioiodide uptake into prostate cancer cells in vitro and into tumors in vivo. Furthermore, Ad5/3-Delta24-hNIS with radioiodide was significantly more effective than virus alone in mice with prostate cancer xenografts. CONCLUSIONS: These results suggest that oncolytic adenovirus-mediated targeted radiotherapy might be a potentially useful option for enhancing the efficacy or adenoviral virotherapy.
Authors: Maria Rajecki; Aki Kangasmäki; Leena Laasonen; Sophie Escutenaire; Tanja Hakkarainen; Jarmo Haukka; Ari Ristimäki; Kalevi Kairemo; Lotta Kangasniemi; Timo Kiljunen; Timo Joensuu; Sari Pesonen; Akseli Hemminki Journal: Mol Ther Date: 2011-04 Impact factor: 11.454
Authors: Kenneth N Barton; Hans Stricker; Mohamed A Elshaikh; Jan Pegg; Jingfang Cheng; Yingshu Zhang; Kastytis C Karvelis; Mei Lu; Benjamin Movsas; Svend O Freytag Journal: Mol Ther Date: 2011-05-17 Impact factor: 11.454
Authors: Yu-Ping Liu; Jiahu Wang; Victoria A Avanzato; Jamie N Bakkum-Gamez; Stephen J Russell; John C Bell; Kah-Whye Peng Journal: Gynecol Oncol Date: 2014-01-14 Impact factor: 5.482
Authors: Maria Rajecki; Mirkka Sarparanta; Tanja Hakkarainen; Mikko Tenhunen; Iulia Diaconu; Venla Kuhmonen; Kalevi Kairemo; Anna Kanerva; Anu J Airaksinen; Akseli Hemminki Journal: PLoS One Date: 2012-03-07 Impact factor: 3.240